The drug abuse problem in general and the widespread use of marijuana, in particular, have focused attention on the chemistry and pharmacology of the plant Cannabis Sativa. In the decade since the discovery of the cannabinoid receptors, much progress has been made in the cannabinoid field. It has been established that there are at least two types of cannabinoid receptors; CB1 receptors which are present both inside and outside the central nervous system (CNS) and CB2 receptors which are found mainly in the periphery. Two main endogenous ligands have been discovered, anandamide (AEA) and 2-arachidonylglycerol (2-Ara-G1). Also known as endocannabinoids, they are both present in central as well as peripheral tissues. The long term goal of this program is to develop Structure Activity Relationships (SAR) of AEA which are eicosanoids, and bear no chemical/structural relationship to other cannabinoids. We feel that SAR of AEA will be critical for understanding how AEA and other cannabinoids interact with the same receptor.
Our specific aims are (i) to continue to examine the SAR of arachidonic acid portion of AEA (ii) to develop AEA/THC (tetrahydrocannabinol) hybrids (iii) to develop novel anandamide membrane transporter (AMT) probes and (iv) to synthesize hydroxylated AEA analogs as potential metabolites of AEA. The synthesis of these analogs and their subsequent biological evaluation will provide us with more potent agonists, partial agonists and antagonists in the AEA series. This may result in the discovery of a silent antagonist with an AEA template and could lead to the discovery of other cannabinoid subtype receptors, reveal mechanisms involved in brain function, and lead to the development of therapeutic drugs in the areas of inflammation, pain, vasodilation, antitumor therapy and other CNS related diseases. The proposed study will increase our understanding of the pharmacological action of this important class of compounds, leading to the discovery of new drugs for the health care field.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA008904-12
Application #
7213453
Study Section
Molecular, Cellular and Developmental Neurosciences 2 (MDCN)
Program Officer
Hillery, Paul
Project Start
1995-02-01
Project End
2009-03-31
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
12
Fiscal Year
2007
Total Cost
$194,377
Indirect Cost
Name
Organix, Inc.
Department
Type
DUNS #
161843057
City
Woburn
State
MA
Country
United States
Zip Code
01801
Breivogel, Christopher S; Puri, Vanita; Lambert, Jonathan M et al. (2013) The influence of beta-arrestin2 on cannabinoid CB1 receptor coupling to G-proteins and subcellular localization and relative levels of beta-arrestin1 and 2 in mouse brain. J Recept Signal Transduct Res 33:367-79
Bisogno, Tiziana; Burston, James J; Rai, Ravi et al. (2009) Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 4:946-50
Breivogel, Christopher S; Lambert, Jonathan M; Gerfin, Steven et al. (2008) Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- mice. Behav Pharmacol 19:298-307
Bourne, Caryl; Roy, Sucharita; Wiley, Jenny L et al. (2007) Novel, potent THC/anandamide (hybrid) analogs. Bioorg Med Chem 15:7850-64
Bisogno, Tiziana; Cascio, Maria Grazia; Saha, Bijali et al. (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761:205-12
Wiley, Jenny L; Razdan, Raj K; Martin, Billy R (2006) Evaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice. Life Sci 80:24-35
Ligresti, Alessia; Cascio, Maria Grazia; Pryce, Gareth et al. (2006) New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol 147:83-91
Kaplan, Barbara L F; Ouyang, Yanli; Herring, Amy et al. (2005) Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2'-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide. Toxicol Appl Pharmacol 205:107-15
Vandevoorde, Severine; Saha, Bijali; Mahadevan, Anu et al. (2005) Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun 337:104-9
Wiley, Jenny L; Smith, Forrest L; Razdan, Raj K et al. (2005) Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice. Eur J Pharmacol 510:59-68

Showing the most recent 10 out of 19 publications